When medical evidence alone is simply not enough

Cancer

Volumn 115, Issue 12, 2009, Pages 2602-2604

  O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; INTERFERON; MITOMYCIN; THIOTEPA;

BCG VACCINATION; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; EUROPE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 67649216119     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24312     Document Type: Editorial

References (16)

1. Madeb R, Golijanin D, Noyes K. Treatment of non-muscle invading bladder cancer: do physicians in the United States practice evidence based medicine? Cancer. 2009;115:2660-2670.
2. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology. 2003;62:1083-1088.
3. Chung D, Hersey K, Fleshner N. Differences between urologists in United States and Canada in approach to bladder cancer. Urology. 2005;65:919-925.
4. Joudi FA, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24:344-348.
5. Smith JA, Labasky RF, Cockett AT, et al. Bladder cancer guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, TIS). J Urol. 1999;162:1697-1701.
6. Medical Research Council. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol. 1985;57:680-685.
7. Lunglmayr G, Czech K. Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors. J Urol. 1971;106:72-74.
8. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 pt 1):2186-2190, quiz 2435.
9. Racioppi M, Porreca A, Foschi N, et al. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Urol Int. 2005;75:373-375.
10. Witjes JA, Melissen DOTM, Kiemeney LALM. Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. Eur Urol. 2006;49:478-484.
11. Clarke NS, Basu S, Prescott S, Puri R. Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists. BJU Int. 2006;97:716-719.
12. Mostafid AH, Rajkumar RGN, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU Int. 2006;97:509-512.
13. O'Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am. 2005;32:121-131.
14. American Urological Association Bladder Cancer Clinical Guideline Update Panel. Guideline for the management of nonmuscle invasive bladder cancer (staged Ta, T1 and Tis): 2007 update. Available at: http://www.auanet.org/guidelines/ bladcan07.cfm Accessed April 25, 2008.
15. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen A, Bohle A, Palou J. Guidelines on Ta T1 (non-muscle invasive) bladder cancer (2008 update). European Association of Urology. Available at: http://www.uroweb.org/nc/ professionalresources/guidelines/online/ Accessed April 25, 2008.
16. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-1330.